New Guideline Includes Immunotherapy
In March, the immunotherapy Tecentriq® (atezolizumab) became the first to be included in NCCN Treatment Guidelines for metastatic breast cancer. It can be used along with Abraxane® (nab-paclitaxel) to treat patients with locally advanced or metastatic triple negative breast cancer who have a tumor that tests positive for PD-L1.
Immunotherapy is a type of biological therapy that uses the body’s immune system to fight cancer. There are many new types of immunotherapies being developed and researchers are actively studying which ones might work in patients with breast cancer.
Below you will find relevant information about MBC treatment guidelines as well as research news and clinical trials on immunotherapy for metastatic breast cancer.
- MedPage Today: Immunotherapy Makes First Appearance in NCCN Breast Cancer Guideline
- Metastatic Trial Talk: From the Experts: MBC Treatment Guidelines
- CureToday: Breast Cancer Gets A Boost From Immunotherapy
- Cancer.gov: Immunotherapy: Side Effects and Complications
- Cancer Research Institute: Immunotherapy for Breast Cancer
- Cancer.net: Immunotherapy for Breast Cancer: Is it an option?
- MedPage Today: No Survival Benefit with Immunotherapy
- Metastatic Trial Talk: MBC Research News: Immunotherapy & Metastatic Breast Cancer
- BreastCancerTrials.org: Current immunotherapy clinical trials for Breast Cancer